This paper examines the nature of a stable complex consisting of a GPCR heterotetramer and AC5 equivalents. The authors use TAT-TM peptides mimicking various transmembrane domains of the A2A-adenosine receptor, the D2 dopamine receptor and AC5. They also use BiFC and PLA as primary outcome measures examining complex formation from different vantage points. Their premise is that GPCR homodimers form heterotetramers that contain effectors and presumably heterotrimeric G proteins in a stable, pre-assembled signalling complex. I am supportive of this idea but I have several concerns regarding the core premise and how they have performed and interpreted their data.
1) Using BiFC they "force" dimerization of either homodimer or the A2AR/D2R heterodimer. 48 hours after transfection they add TAT-TM peptides for 4 hours and test for their ability to disrupt complexes as measured by a loss of fluorescence. They may have confirmed that such tagged versions of their receptors and AC5 remain functional (which they should reference) or if not, they should demonstrate here. In my experience such reconstituted dimers do not come apart. So what do their experiments actually show? Prevention of the formation of new dimers? They should demonstrate this more directly. I am concerned that not all the TAT-TM peptides get into the membrane with the same efficacy-how do the authors control for that? The scrambled peptides that work do not give me confidence in this regard either.
2) If these forced dimers don't come apart, how do we interpret the effects of receptor ligands on fluorescence? BiFC is a crude tool to examine the conformational dynamics of protein complexes in response to ligands unless it can be demonstrated that such complexes can come together and apart in a dynamic equilibrium.
3) I have similar concerns for the PLA experiments-do they suggest the dimers are coming apart in response to TAT-TMs? This goes against the core argument the authors are trying to make. Also, the authors could demonstrate the PLA does not occur in the absence of receptor expression in HEK 293 cells.
4) I don't buy the notion that all heterotetramers are dimers of homodimers as the authors suggest in the introduction. The dynamics of GPCR complexes are highly variable depending on the molecular and cellular context assayed. Personally, I think metastability is the core feature of these complexes and I like the approach taken here to examine it. Perhaps the authors could be more nuanced in the introduction. The question of proximity versus stability is the key issue here-perhaps a third technique like co-immunoprecipitation with and without TAT-TM or agonist could settle the issue?
5) The elephant in the room is what happens to G protein partners in these complexes? Are they important for formation of the R/R/E complexes or merely transducers of conformational information in response to agonist.
Minor comments
1) The word "strong" in the abstract is a relative term.
Reviewer #2 (Remarks to the Author):
The manuscript "Functional pre-coupled complexes of receptor heteromers and adenylyl cyclase" aims to address the existence of pre-coupling between GPCRs (A2A and D2R) and transmembrane adenylyl cyclase type 5 using engineered mimetic transmembrane domain peptides to disrupt interactions. Although it is quite accepted that GPCRs and G proteins must be in close proximity to their effectors this remains a fundamental question in the field not much is known on whether these different actors can form a complex in absence of receptor ligand. The study uses fluorescencebased technology to elucidate protein/protein organization in association with computational models and signaling experiments in both heterologous system and primary cells. Overall, this is an elegant work which provides new insights on how GPCR heteromers and AC5 may pre-form a functional complex and how ligand may rearrange these complexes. The authors should consider the following:
1-
Authors assumed that TMs mimetic peptides are all correctly orientated and integrated in the membrane on the basis of the TAT-fused strategy. However, no evidences are provided. This is important to check especially for TM2,3 and 7 of A2A and D2R as they have no apparent effect on Bimolecular Fluorescence complementation.
2-
How were determined the time of pretreatment (4 hours) and the concentration of peptide (4 M)? Moreover, Dose -responses may allow to establish the relative IC50 for each peptide as any other pharmacological tool.
3-
BRET data suggest the formation of a complex between AC5 and D2R or AC5 and A2A. Although non-fluorescent receptor is added in the experiment to allow the formation of the heterotetramer, authors did not verify whether AC5 overexpression may affect the heteromerization of A2A with D2R. This needs to be verified.
4-
In line with previous comment, AC5 TM peptides should be tested on A2A/D2R heteromer formation as negative controls as well as the effect of A2A TMs or D2R TMs on A2A/AC5 and D2R/AC5 respectively.
5-
Authors proposed an "hypothetical" model in which AC5 and heterotetramers (A2A/D2R) associate in a linear manner ( fig. 3g and supp fig. 3 ) suggesting a certain stochiometry. This is an interesting hypothesis however, this is mostly based on overexpressed proteins. Considering the relative expression of both receptors in AC5 in striatal neurons, authors should comment on how this may also be true in native cells. PLA for AC5/D2R or AC5/A2A in neurons may reveal the preassemble complexes in a relevant cell model.
6-
TM5n impaired association between receptors and AC5 is as good as TM5b, but not TM5 in absence of agonist. Additionally, authors hypothesized that TM5n may be part of intracellular IL2 of AC5 and involved in pre-coupling with receptors. Thus, a scramble IL2 peptide would be a good negative control here.
Minor comments:
1-Line 190. TM4n also behave as a negative control peptide and is not mentioned.
2-
How the association between GPCRs and AC5 would change if agonists were added? Since TMs from M1 domain show a marked increased sensitivity to TM2,3,5 and 6 disrupting peptides, some changes in the association between AC5 and receptors may occur.
3-
Would co-treatment with several peptides have an additive effect on A2A-D2R or AC5/receptors complexes?
Reviewer #3 (Remarks to the Author):
In this current study Navarro and co-workers addressed highly important questions in the GPCR field related to homo-or hetero-oligomerization and associated GPCR/effector-complex constitution. Higher order complexes between GPCR protomers, homo-or heteromeric, are in fact known and evidenced for many class A and other classes of GPCRs, but detailed information regarding structural prerequisites or functional consequences/relations of those complexes (GPCR interactome) is rarely available so far. Approaches to obtain experimental data deciphering molecular backgrounds including structural (e.g. active versus inactive state conformations) and functional (signaling) aspects are still challenging with respect to appropriate methods.
To the authors credit they comprehensively studied focused issues, means a systematic "multiplesite" perspective on potentially contacting partners and functional consequences.
The techniques used in this study are appropriate, the received data are not over-interpreted in the conclusions and discussion. The context is described well throughout the manuscript and under consideration of previously and recently published information.
To the reviewers opinion this study can be seen as a progressive contribution and suggestion to several specific but also general aspects in the GPCR field. This concerns the TMH6-TMH6 interface between GPCR homomers, the simultaneous heterooligomeric dimer-dimer interface at TMH4-TMH5, the independence of homodimer-interfaces on the activity state, moreover the concluded pre-coupling or close spatial distance of AC to the inactive receptors, changes in receptor-AC interaction during activation, and finally implications for canonical signaling (Gs and Gi signaling in heteromeric GPCR complexes). The results may also have impact on parameters or mechanisms related to selectivity of GPCR signaling, but definitively they contribute information on pre-coupling partners of GPCRs, at least for the studied receptors.
Moreover, the manuscript is well balanced between the particular sections and the data are presented convincing.
Major points:
Are data available proving on GPCR/AC interaction without available G-protein? Or is a Gprotein/AC pre-complex a prerequisite for interaction with the GPCR (or a GPCR/G-protein precomplex for interaction with AC, respectively)?
Minor points:
-
The results and suggested scenario of receptor/AC pre-coupling must be strongly dependent (independently from the used method) also on the capacity of the investigated receptors to signal in a ligand-free (constitutive) basal state. It would be helpful to clarify this aspect for A2A and the D2R in the discussion section.
It is of note, that both homodimers here are characterized by a TMH6-TMH6 interface. A discussion is needed how a TMH6-TMH6 interface in the homodimers may have impact on receptor activation (or how receptor activation can occur in such a constellation), because TMH6 outward movement is a significant feature of GPCR activation from a structural perspective and such a postulated interface may constrain this helix. (Rose et al., 2010, Brit J Pharmacol, 159, 738 Schmidt et al. (2003 , Mol Cell 12, 1287 , in their study about the differential association and dissociation of specific complexes of NF-κB with two different isoforms of the I-κB inhibitor; also by Guo et al. (2005 , J Biol Chem, 280, 1438 , in experiments about the βγ-dependent dissociation of complexes of phospholipases Cβ 2
In these two points, the reviewer expresses his/her concerns about two assumptions regarding BiFC. First, that fusion of the two complementary YFP fragments "forces" the intermolecular interaction between the proteins to which they are separately attached. In fact, it is the complex formation between the two interacting proteins what forces the fusion of the YFP fragments
and Cδ 1 ; and by Anderie and Schmid (2007, Cell Biol Int, 31, 1131) Jastrzebska et al., J Biol Chem, 2015, 290, 25728; cited 
in the text).
These arguments (and references) that stress the ability of TM peptides to specifically disrupt BiFC and PLA in mammalian cells will now be included in a few sentences in the Discussion. Following the reviewer's advice, we have added control experiments (cAMP accumulation) demonstrating the functionality of all receptors attached to the full or fragmented YFP (Supplementary Fig. 1 Fig. 3a and  3b) , we have also included the controls indicated by the reviewer, showing the lack of A2AR-D2R complexes in HEK cells only expressing A2AR or D2R.
4. I don't buy the notion that all heterotetramers are dimers of homodimers as the authors suggest in the introduction. The dynamics of GPCR complexes are highly variable depending on the molecular and cellular context assayed. Personally, I think metastability is the core feature of these complexes and I like the approach taken here to examine it. Perhaps the authors could be more nuanced in the introduction. The question of proximity versus stability is the key issue here-perhaps a third technique like co-immunoprecipitation with and without TAT-TM or agonist could settle the issue?
We agree with the reviewer about being less categorical in the introduction about the evidence for heterotetramers as composed of heteromers of homodimers. Therefore, in the Introduction, we replaced "indicate" by "suggest", when telling about growing evidence for GPCR homodimers as a common GPCR unit. And, in the sentence "heteromers can be viewed as constituted by different interacting homodimers", we replaced "can" by "could". About the questions of proximity and stability of putative protein-protein interaction, we totally agree with the reviewer about the need for more than one technique. That is why we used BiFC and PLA for the interactions between GPCRs and BiFC and BRET for the interactions between GPCRs and AC5, which in our experience and that of other research groups, there are more valuable methods to study direct interactions between GPCRs or GPCRs and signaling proteins than co-IP. The reviewer would probably agree with the fact that co-IP experiments with and without peptides would not lead to unequivocal information. Indirect interactions cannot be ruled out with co-IP, making almost impossible to know whether all the proteins found form one single complex with the bait protein, or whether they exist in different subcomplexes. Nevertheless, a third technique, BRET plus double complementation of BRET biosensors, had already been used to study A2AR-D2R heterotetramers in a previous study referenced in the text (Bonaventura et al., 2015)
. Also, and in agreement with reviewer #2, a third technique, PLA, was now used to demonstrate complexing of endogenous AC5 with A2AR and with D2R in striatal cells (Supplementary Fig. 7 ).
The elephant in the room is what happens to G protein partners in these complexes?
Are they important for formation of the R/R/E complexes or merely transducers of conformational information in response to agonist. 
This is an important question already addressed in the first

Minor comment:
The word "strong" in the abstract is a relative term.
We deleted "strong" from the abstract
Answers to Reviewer #2 1. Authors assumed that TMs mimetic peptides are all correctly orientated and integrated in the membrane on the basis of the TAT-fused strategy. However, no evidences are provided. This is important to check especially for TM2,3 and 7 of A2A and D2R as they have no apparent effect on Bimolecular Fluorescence complementation. He et al. (2011, Neuron, 69, 120; previously and increasing amounts of AC5 cDNA. No BRET differences were observed between the results obtained with 0, 0.3, 1.0 and 3.0 μg of AC5 cDNA (56 ± 7, 53 ± 6, 53 ± 3 and 52 ± 4 mBU, respectively) . These additional data have been added in the Results section.
The ability of TAT-TMs to integrate in the plasma membrane in an orientation-specific manner was previously demonstrated by the elegant studies of
cited in the Methods section and now explicitly mentioned in the Results section), when determining the interface of the mu-delta-opioid receptor heteromer. Their method implied the immuno-cytochemical detection of TM peptides with GST fused to the N-terminus and TAT fused to either the N-or the C-terminus in permeabilized and non-permeabilized neuronal preparations. The localization of the TAT sequence determined the localization of GST, facing the intra-or the extracellular space. The corresponding TAT-TM peptides where always integrated in the membrane
Following the reviewer's comment, as an additional control, we also verified if overexpression of AC5 could alter A2AR-D2R heteromerization with BRET experiments in HEK-293T cells transfected with A2AR
4. In line with previous comment, AC5 TM peptides should be tested on A2A/D2R heteromer formation as negative controls as well as the effect of A2A TMs or D2R TMs on A2A/AC5 and D2R/AC5 respectively. (Supplementary Fig. 5 ). Sentence included in the Results Section.
Following the reviewer's comment, as additional negative controls, we also tested AC5 TM1 to TM12 peptides on A2AR-nYFP-D2R-cYFP complementation and all the D2R TM and A2AR TM peptides on AC5-nYFP-A2AR-cYFP and AC5-nYFP-D2R-cYFP complementation, respectively, in the absence of ligands
5. Authors proposed an "hypothetical" model in which AC5 and heterotetramers (A2A/D2R) associate in a linear manner ( fig. 3g and supp fig. 3) Fig. 7 ). This information and the corresponding additional methods have been added in the text. Please, see answer to the same point raised by reviewer #1 (point 5).
TM5n impaired association between receptors and AC5 is as good as
Minor points:
-The results and suggested scenario of receptor/AC pre-coupling must be strongly dependent (independently from the used method) also on the capacity of the investigated receptors to signal in a ligand-free (constitutive) basal state. It would be helpful to clarify this aspect for A2A and the D2R in the discussion section.
This is an important point we are in fact investigating. We have obtained experimental results that indicate that the previously described constitutive activity of the A2AR (Fernando-Duenas et al., ACS Chem Biol, 2014 , 9, 2496 
